Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

1.600 +0.050 (+3.23%)
Streaming Delayed Price Updated: 1:19 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu Biopharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today! 
Via InvestorPlace
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
  
Via Benzinga
Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
Via Benzinga
Aytu BioPharma Announces Launch of Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million. 
Via Benzinga
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced... 
From Aytu BioPharma, Inc.
Via AccessWire
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
Aytu BioPharma Commences Late-Stage Genetic Disorder Study
Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS). 
Via Benzinga
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
Via ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of... 
From Aytu BioPharma, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma: Q3 Earnings Insights
Aytu BioPharma (NASDAQ:AYTU) reported its Q3 earnings results on Monday, May 16, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Aytu BioPharma beat estimated... 
Via Benzinga
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and... 
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu... 
From Aytu BioPharma, Inc.
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million. 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals'... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S.... 
From Aytu BioPharma, Inc.
Via AccessWire
Exposures Product Safety
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Participate in the 34th Annual Roth Conference
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of... 
From Aytu BioPharma, Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS